8-K: CareCloud Faces Nasdaq Non-Compliance After Director's Death

CareCloud, Inc. announced the passing of independent director John N. Daly, leading to non-compliance with Nasdaq's independent director and Audit Committee composition rules.

Summary

• CareCloud, Inc. reported the passing of Mr. John N. Daly, an independent director, on November 24, 2025.
• Mr. Daly served as a director since July 2014 and was a member of the Audit Committee and chairman of the Compensation Committee.
• His passing resulted in the company's non-compliance with Nasdaq Listing Rule 5605(b)(1), which requires a majority of the Board of Directors to be independent.
• The company also became non-compliant with Nasdaq Listing Rule 5605(c)(2)(A), requiring the Audit Committee to consist of at least three members.
• Nasdaq notified the company on November 25, 2025, of an available cure period, which expires on the earlier of the company's next annual meeting of shareholders or November 24, 2026.
• The Board plans to regain compliance by appointing an additional independent director to fill the vacancy on the Audit Committee at its earliest opportunity.

Sentiment

Score: 3

Explanation: The passing of a director and subsequent Nasdaq non-compliance is a negative event, though the company has a defined cure period and a stated plan to address it, mitigating immediate severe concerns.

Negatives

• The passing of Mr. John N. Daly, a respected and long-serving independent director.
• Immediate non-compliance with Nasdaq Listing Rule 5605(b)(1) regarding board independence.
• Immediate non-compliance with Nasdaq Listing Rule 5605(c)(2)(A) regarding Audit Committee composition.

Risks

• Potential delisting from Nasdaq if the company fails to regain compliance with listing rules within the specified cure period.
• Operational disruption or increased scrutiny due to vacancies on key board committees (Audit and Compensation).

Future Outlook

The company plans to regain compliance with Nasdaq listing rules at its earliest opportunity by appointing an additional independent director to fill the vacancy on the Audit Committee.

Management Comments

• The Company deeply regrets to announce that Mr. John N. Daly, a respected director of the Company, passed away on November 24, 2025.

Industry Context

This event highlights a common corporate governance challenge faced by publicly traded companies when key independent directors depart, necessitating prompt action to maintain compliance with exchange listing standards. Such situations are routinely addressed through board appointments to ensure continuity and adherence to regulatory requirements.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Face potential risk of delisting if the company fails to regain Nasdaq compliance, which could impact share liquidity and valuation.
• Board of Directors: Requires immediate action to identify and appoint a suitable independent director to fill the vacancy and restore committee composition.
• Employees: May experience a period of uncertainty regarding corporate governance, though the direct operational impact is likely minimal.

Next Steps

• Appoint an additional independent director to the Board.
• Fill the vacancy on the Audit Committee with an independent director.
• Regain compliance with Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2)(A) within the cure period.

Key Dates

Recommendation

The passing of a long-serving independent director is a regrettable event that has led to immediate non-compliance with Nasdaq listing rules regarding board independence and Audit Committee composition. While this is a negative development, the company has promptly notified Nasdaq and has a defined cure period until November 24, 2026, or its next annual meeting, to regain compliance. Management has also stated a clear intention to appoint a new independent director to resolve the issue. Investors should monitor the company's progress in appointing a suitable replacement and regaining compliance, but the current situation does not warrant an immediate sell-off given the clear path to resolution.

Keywords

CareCloud, CCLD, Nasdaq, Listing Rules, Corporate Governance, Independent Director, Audit Committee, Compensation Committee, SEC Filing, 8-K